Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.44 |
| ▸ | BRD4 | O60885 | 14/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | PDXK | O00764 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | NEK3 | P51956 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935600 | 0.94 | PLK1 (0.40) | PLK1BRD4BRDTDDB1CRBN | |
| SCHEMBL25031288 | 0.92 | PLK1 (0.54) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL30501293 | 0.92 | PLK1 (0.54) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL30501315 | 0.86 | PLK1 (0.53) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL25031322 | 0.86 | PLK1 (0.53) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL25029381 | 0.86 | PLK1 (0.49) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL25819018 | 0.85 | PLK1 (0.67) | PLK1BRD4BRDTPLK3 | |
| SCHEMBL25031474 | 0.81 | PLK1 (0.48) | PLK1BRD4BRDTPDXKWEE1 | |
| SCHEMBL25034982 | 0.80 | PLK1 (0.52) | PLK1BRD4BRDTPTK2DCLK1 | |
| SCHEMBL25034774 | 0.79 | PLK1 (0.65) | PLK1BRD4BRDTPLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 903/4885BRDT 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.